Valziflocept

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameValziflocept
Drug Alias NameSHP-652BAX-1810FcγRIIbSM-101TAK-752 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor II-b antagonists
TargetsLow affinity immunoglobulin gamma Fc region receptor II-b
Therapy Area/IndicationsGlomerulonephritis, IGA
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSuppremol
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBaxalta IncorporatedOak Hill Bio Inc
Active IndicationsN/A
Inactive IndicationsGlomerulonephritis, IGA

Other Information

ATC CodeN/A
Related LinksN/A